Poster Abstracts • OFID 2017:4 (Suppl 1) • S493 empiric treatment of NF in patients meeting specific criteria. After 48 hours, the guidelines recommend discontinuing vancomycin if resistant Gram-positive organisms are not identified. An analysis of vancomycin use for NF at our institution revealed 35% of patients had vancomycin discontinued appropriately at 48 hours. Based on these results, a vancomycin stewardship team defined criteria for continuation of vancomycin past 48 hours and increased surveillance of vancomycin usage through AST oversight. The objective of this study is to assess the incidence of vancomycin discontinuation at 48 hours with the new criteria of use and the addition of pharmacist led stewardship.
Background. Pre-transplant screening for VRE is commonly performed among patients prior to hematopoietic cell transplantation (HCT) although its role in prevention of horizontal transmission is controversial. The impact of pre-transplant VRE colonization on antimicrobial stewardship and use of VRE therapy is unknown. The purpose of this investigation is to determine whether pre-transplant VRE colonization affects the use of VRE therapy among patients during the first 100 days post-transplant.
Methods. We analyzed patients >18 years old within the first 100 days post-allogeneic HCT at a cancer center from September 1, 2007 to August 31, 2016 from a prospectively collected database. We performed retrospective chart review among patients who did and did not develop VRE bacteremia to obtain antimicrobial utilization data for agents with in vitro activity against VRE based on colonization status. Patients colonized post-HCT and those with positive surveillance blood cultures were excluded from analysis. Continuous variables were assessed using t-tests or Mann-Whitney U tests for normal or non-normal data respectively.
Results. Of 1402 allogeneic HCT patients, 203 (14%) were colonized pre-transplant. Among 22 (1.6%) patients who developed VRE bacteremia, 19 (86%) were colonized pre-transplant. Eight (42%) colonized patients received empiric VRE therapy within 24 hours of blood culture collection compared with 0 (0%) of non-colonized patients (P = 0.23). Among the 1371 patients who did not develop VRE bacteremia, 66 (5%) received VRE therapy. 32/179 (18%) of the colonized group received VRE therapy compared with 34/1192 (3%) non-colonized (P <.001). The median duration of VRE therapy was 3 days in the colonized group and 2 among non-colonized (P = 0.86). Indications for VRE therapy among colonized patients without bacteremia were empiric therapy (63%), therapy for VRE isolated from non-blood sites (19%), alternative therapy for non-VRE Gram-positive infection (13%), and unknown (6%).
Conclusion. In our population, VRE-colonized patients received significantly more VRE therapy than non-colonized patients in the absence of VRE bacteremia. Among patients who developed bacteremia, less than half received timely initiation of empiric therapy.
Disclosures. S. Pergam, Merck: Consultant and Investigator, Consulting fee. Background. Neutropenic fever (NF) is a serious complication of chemotherapy. Approximately 23% of NF cases are related to bacteremia, with higher mortality attributed to infections caused by Pseudomonas aeruginosa. Therefore, empiric anti-pseudomonal (AP) coverage is critical for patients with NF. However, no recommendations exist as to which AP agent is preferred. Traditionally at Froedtert Hospital, meropenem was prescribed as empiric therapy for NF despite a low incidence of multidrug resistant (MDR) pathogens. In June 2016, Froedtert Hospital implemented guidelines for the treatment of NF to guide initial AP antibiotic selection based on risk factors for MDR gram-negative infections. Risk stratification reserves broadest spectrum antimicrobials (eg, meropenem) for patients at highest risk of MDR organisms.
Evaluation of a Risk Stratification Guideline for the Treatment of Neutropenic Fever in Oncology Patients
Methods. A retrospective chart review was completed to evaluate NF treatment pre-guideline (Jan 1-June 30, 2015) and post-guideline implementation (June 23-Dec 31, 2016). All patients ≥18 years old, admitted to Froedtert Hospital that met NF definition criteria were included.
Results. A total of 79 patients in the pre-guideline implementation group (pregroup) and 91 patients in the post-guideline implementation group (post-group) were included. In the pre-group, only 26 (32.8%) patients would have met criteria to receive meropenem, however 71 (89.8%) received it. In comparison, in the post-group, 29 (41.8%) patients qualified to receive meropenem based on risk-stratification and 8 patients (8.8%) received it, due to primary teams opting for non-carbapenem APs despite meeting criteria for meropenem. In the post-group, there were 4 cases of infections with a MDR organism requiring meropenem. All 4 patients met guideline criteria to receive meropenem (2 patients received meropenem, 2 did not due to guideline noncompliance). Therefore, the incidence of appropriate empiric AP therapy recommended by the NF guideline was 100%. 30-day all-cause mortality was 17.7% in the pre-group and 15.5% in the post-group.
Conclusion. Appropriate use of a NF risk stratification tool resulted in a significant reduction in unnecessary AP carbapenem use without compromising antimicrobial coverage of isolated organisms or patient outcomes.
Disclosures. All authors: No reported disclosures. Background. There is a demand for stewardship implementation and research in ambulatory and SOT populations. Few studies focus on outpatient stewardship interventions, and none has focused on timely recognition of CMV in outpatient SOT recipients. This study sought to determine the effect of real-time CMV result notification paired with pharmacist intervention on virologic and clinical outcomes in outpatient SOT recipients.
Outpatient Antimicrobial Stewardship Intervention Targeting Cytomegalovirus (CMV) Viremia in Solid Organ Transplant (SOT) Recipients
Methods. Quasi-experimental study comprised of two 6-month phases. In the pre-intervention phase, pharmacists were not involved in management of outpatient CMV viremia. In the intervention phase, pharmacists received real-time email notification of positive blood CMV results for review and intervention as necessary. The primary endpoint was rate of viremia eradication at 21 days from therapy initiation. Secondary endpoints: time to antiviral initiation and viremia eradication, rate of CMV invasive disease and hospital admission, and adverse drug events.
Results. 88 of 213 screened patients were included in the primary analysis (n = 49 and 39 in the pre-intervention and intervention groups, respectively). Baseline characteristics were similar, including transplant type (34% vs. 41% liver, 24% vs. 28% kidney, 14% vs. 17% lung, 14% vs. 10% heart), CMV serostatus (53% vs. 64% D+/R-), and maintenance immunosuppression. A total of 73 recommendations were made with 89% acceptance. Baseline CMV viral load >10,000 IU/mL occurred in 12 (24%) vs. 6 (15%) patients (P = 0.29). Of treated patients, 42 (85%) vs. 32 (82%) achieved CMV eradication at 21 days (P = 0.64), 10 (20%) vs. 5 (12%) required admission for CMV management (P = 0.35), 7 (14%) vs. 3 (7%) developed CMV invasive disease (P = 0.50), and 29 (60%) vs. 25 (66%) received antiviral within 5 days (P = 0.61). There were no statistically significant differences in time to antiviral initiation (45 vs. 41 hours; P = 0.64) or viremia eradication (19 vs. 18 days; P = 0.44).
Conclusion. CMV eradication at 21 days was not significantly different between groups; however, fewer patients in the intervention experienced elevated baseline viral load, CMV invasive disease, and hospital admission. These secondary endpoints suggest possible benefit from the intervention and warrant further characterization and study.
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